Project PHONOTYPE: Validation of smartphone-based digital phenotyping markers for detecting amotivation symptoms in young people with depression

Grantholders

  • Dr Alexis Whitton

    University of New South Wales, Australia

  • Prof dr Sunil Gupta

    Deakin University, Australia

  • Prof Jill Newby

    Black Dog Institute, Australia

  • Dr Aliza Werner-Seidler

    University of New South Wales, Australia

  • Prof Helen Christensen

    Black Dog Institute, Australia

  • Prof Svetha Venkatesh

    Deakin University, Australia

  • Dr Bridianne O'Dea

    University of New South Wales, Australia

  • Artur Shvetcov

    Black Dog Institute, Australia

  • Mrs Emma Elder

    Black Dog Institute

  • Dr Leonard Hoon

    Swinburne University of Technology, Australia

  • Prof Rajesh Vasa

    Deakin University, Australia

  • Dr Thin Nguyen

    Deakin University, Australia

  • Prof Kon Mouzakis

    Deakin University, Australia

  • Dr Alexis Whitton

    University of New South Wales, Australia

Project summary

Young people with depression who experience loss of interest and motivational drive (amotivation symptoms) respond poorly to first-line depression treatments. New treatments for amotivation symptoms have emerged (e.g., Positive Affect Therapy), and if delivered to the right young people at the right time, could improve treatment outcomes. In project PHONOTYPE, will investigate whether digital signals collected from smartphones are useful for identifying young people with amotivation symptoms. The key goals are to determine whether digital markers converge with self-reported amotivation symptoms in cross-sectional and longitudinal datasets, whether they predict a more severe depressive illness course, and whether they are useful for identifying young people who respond favourably to motivation-targeted treatment. We will use artificial intelligence (AI) to identify digital signals, using our custom-built AI-enhanced digital phenotyping and clinical trial platform. Our team of international mental health leaders, lived experience research specialists, and AI experts, will leverage existing richly-phenotyped longitudinal studies of adolescents and clinical trials of young adults with depression (N>7,500). To establish generalisability and clinical utility, we will conduct two new trials and establish a Digital Phenotyping Databank. Throughout, we will implement a capacity-building program to ensure lived experience advisors engage as peers across leadership, governance, design, and translation.